Compare TDOC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | NVAX |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2015 | 1996 |
| Metric | TDOC | NVAX |
|---|---|---|
| Price | $9.71 | $8.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 9 |
| Target Price | $7.56 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 4.3M | 4.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 80.58 | ★ 309.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | $1,123,479,000.00 |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 18.41 | ★ 64.69 |
| 52 Week Low | $4.40 | $6.20 |
| 52 Week High | $9.89 | $11.85 |
| Indicator | TDOC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.86 | 36.24 |
| Support Level | $6.62 | $7.78 |
| Resistance Level | $9.66 | $10.10 |
| Average True Range (ATR) | 0.41 | 0.40 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 82.40 | 9.91 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.